Site Map | Legal Policy | Privacy Policy

 

News

All Releases
Ligand to Present at the Cowen & Company 30th Annual Healthcare Conference on March 11
Mar 1, 2010
Ligand Announces Fourth Quarter and Full Year 2009 Consolidated Financial Results
Feb 9, 2010
Ligand to Report Fourth Quarter Results on February 9th
Feb 1, 2010
Ligand Completes Acquisition of Metabasis
Jan 28, 2010
Ligand Earns $1 Million in Milestone Payment from Merck & Co., Inc.
Jan 7, 2010
Ligand Completes Neurogen Acquisition
Dec 23, 2009
Ligand Announces Positive Regulatory Opinion in Europe for Revolade for Chronic Immune Thrombocytopenic Purpura
Dec 18, 2009
Ligand and Neurogen Amend Merger Agreement
Dec 17, 2009
Ligand Presents New Preclinical Data on its Lead SARM Molecule LGD-4033 at the Gerontological Society of America Annual Meeting
Nov 20, 2009
Ligand Earns $2 Million in Milestone Payments from Merck & Co., Inc.
Nov 19, 2009
Ligand Pharmaceuticals Announces Third Quarter Results
Nov 5, 2009
Ligand's JAK3 Research Collaboration Extended by Pfizer
Nov 5, 2009
Ligand Updates License Agreement with Exelixis
Nov 2, 2009
Ligand to Acquire Metabasis for Cash and Contingent Value Rights
Oct 27, 2009
Ligand to Hold Third Quarter Results Conference Call on November 5
Oct 26, 2009
PROMACTA Awarded 2009 Prix Galien for Best Biotechnology Product
Oct 5, 2009
Ligand to Present on October 6th at the Fourth Annual JMP Securities Healthcare Focus Conference
Sep 30, 2009
Ligand and GlaxoSmithKline Collaboration Identifies New Compound
Sep 28, 2009
Ligand Presents to Investors at Thomas Weisel Partners Healthcare Conference
Sep 9, 2009
Ligand to Present at Thomas Weisel Partners on September 9
Aug 26, 2009
Showing 1-20 of 204 Page: 1 2 3 ... 11  Next 20
News

Ligand to Present at the Cowen & Company 30th Annual Healthc.......

Ligand Announces Fourth Quarter and Full Year 2009 Consolida.......

Upcoming Events

Q4 2009 Results at BIO CEO Conference

Cowen & Company 30th Annual Healthcare Conference

Investor Relations|News|Presentations & Events|SEC Documents|
Corporate Governance|Stock Information|Email Alerts
LGND - (NASDAQ)
$1.71   + 0.01